Oxysterols and Alzheimer's disease

Acta Neurologica Scandinavica

Volumn 114, Issue SUPPL. 185, 2006, Pages 43-49

  Bjoandrkhem I ^a   Heverin, M ^a   Leoni, V ^a   Meaney, S ^a   Diczfalusy, U ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

27 hydroxycholesterol; Alzheimer's disease; Blood brain barrier; Cholesterol; Oxysterols

Indexed keywords

26 HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN; CHOLESTEROL; DESMOSTEROL; OXYSTEROL;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BRAIN LEVEL; LIPID OXIDATION; NONHUMAN; PATHOGENESIS; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR;

EID: 33745761211     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00684.x     Document Type: Review

References (41)

1. BJÖRKHEM I, MEANEY S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004;24:806-15.
2. WOLOZIN B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004;41:7-10.
3. SPARKS DL, SABBAGH MN, CONNOR DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-7.
4. MEANEY S, BODIN K, DICZFALUSY U, et al. On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J Lipid Res 2002;43:2130-2135.
5. BJÖRKHEM I, DICZFALUSY U. Oxysterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol 2002;22:734-42.
6. LUND EG, GUILEYARDO JM, RUSSELL DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A 1999;96:7238-43.
7. LUND EG, XIE C, KOTTI T, et al. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 2003;278:22980-22988.
8. 2 techniques in vivo and in vitro. J Biol Chem 1997;272:30178-84.
9. LÜTJOHANN D, BREUER O, AHLBORG G, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 1996;93:9799-9804.
10. BJÖRKHEM I, LÜTJOHANN D, DICZFALUSY U, et al. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 1998;39:1594-600.
11. PITAS RE, BOYLES JK, LEE SH, et al. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987;917:148-61.
12. XIE C, LUND EG, TURLEY SD, et al. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res 2003;44:1780-9.
13. PFRIEGER FW. Role of cholesterol in synapse formation and function. Biochim Biophys Acta 2003;1610:271-280.
14. PFRIEGER FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 2003;25:72-78.
15. TEBOUL M, ENMARK E, LI Q, et al. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc Natl Acad Sci U S A 1995;92:2096-100.
16. LUND E, ANDERSSON O, ZHANG J, et al. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol 1996;16:208-12.
17. BJÖRKHEM I, MURI BOBERG K, LEITERSDORF E. Inborn errors in bile acid synthesis and storage of sterols other than cholesterol, 8th edn. New York, McGraw Hill, 2001;2961-88.
18. BJÖRKHEM I. Do oxysterols control cholesterol homeostasis? J Clin Invest 2002;110:725-30.
19. HEVERIN M, MEANEY S, LÜTJOHANN D, et al. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 2005;46:1047-52.
20. LEONI V, MASTERMAN T, PATEL P, et al. Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J Lipid Res 2003;44:793-799.
21. LÜTJOHANN D, STROICK M, BERTSCH T, et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 2004;69:431-8.
22. WECHSLER A, BRAFMAN A, SHAFIR M, et al. Generation of viable cholesterol-free mice. Science 2003;302:2087.
23. OHYAMA Y, MEANEY S, HEVERIN M, et al. Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46 A1): marked insensitivity towards different regulatory axes. J Biol Chem 2006; 3810-20.
24. BRETILLON L, LÜTJOHANN D, STAHLE L, et al. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J Lipid Res 2000;41:840-5.
25. BRETILLON L, SIDÉN Å, WAHLUND LO, et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 2000;293:87-90.
26. LEONI V, MASTERMAN T, MOUSAVI FS, et al. Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 2004;42:186-91.
27. BOGDANOVIC N, BRETILLON L, LUND EG, et al. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 2001;314:45-48.
28. BROWN J III, THEISLER C, SILBERMAN S, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 2004;279:34674-81.
29. LEONI V, MASTERMAN T, DICZFALUSY U, et al. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 2002;331:163-166.
30. LEONI V. On the possible use of oxysterols for the diagnosis and evolution of patients with neurological and neurodegenerative diseases. Thesis. Karolinska Institutet 2006, Stockholm.
31. LÜTJOHANN D, PAPASSOTIROPOULOS A, BJÖRKHEM I, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000;41:195-8.
32. HEVERIN M, BOGDANOVIC N, LÜTJOHANN D, et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 2004;45:186-193.
33. YAU JL, RASMUSON S, ANDREW R, et al. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Neuroscience 2003;121:307-14.
34. KOLDAMOVA RP, LEFTEROV IM, IKONOMOVIC MD, et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem 2003;278:13244-56.
35. SUN Y, YAO J, KIM TW, et al. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 2003;278:27688-27694.
36. KOLSCH H, LÜTJOHANN D, TULKE A, et al. The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Brain Res 1999;818:171-5.
37. DIETSCHY JM, TURLEY SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001;12:105-112.
38. KIVIPELTO M, HELKALA EL, LAAKSO MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-51.
39. HARIK-KHAN R, HOLMES RP. Estimation of 26-hydroxycholesterol in serum by high-performance liquid chromatography and its measurement in patients with atherosclerosis. J Steroid Biochem 1990;36:351-355.
40. BABIKER A, DZELETOVIC D, WIKLUND B, et al. Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid. Scand J Clin Lab Invest 2005;65:365-75.
41. KNEBL J, DEFAZIO P, CLEARFIELD MB, et al. Plasma lipids and cholesterol esterification in Alzheimer's disease. Mech Ageing Dev 1994;73:69-77.